NewAmsterdam Pharma to Present Obicetrapib Clinical Data at 2026 NLA Scientific Sessions

NewAmsterdam Pharma will present new clinical data regarding its lead product candidate, obicetrapib, at the National Lipid Association (NLA) 2026 Scientific Sessions. The company scheduled these presentations to share findings from its ongoing cardiovascular research program with medical professionals and researchers in attendance.

The presentations will focus on the efficacy and safety profiles of obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor currently under investigation for the treatment of patients with dyslipidemia. Researchers will detail specific outcomes from the company’s clinical trials, providing data on the drug’s impact on low-density lipoprotein cholesterol (LDL-C) levels and other cardiovascular markers. These sessions serve as a platform for the company to disclose updated trial results and provide further insight into the therapeutic potential of the treatment within the current lipid-management landscape.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 3, 2026

Author

GOAI